Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve
Shots:
- The P-II (CENTAUR) trial evaluate AMX0035 vs PBO in 137 patients with ALS. The post hoc analyses reported a larger survival benefit in the prespecified ITT analysis
- In the July 2020 cutoff date, results of the final OS ITT analysis showed a longer median survival duration of 6.9mos. & the observed median survival of 25.8mos. over RPSFTM-adjusted median survival of 15.2mos. in PBO, patients treated with AMX0035 continued into the OLE phase which showed 18.8mos. longer median survival duration in a subgroup analysis
- In the Mar 2021 cutoff date, results showed a lower hazard of death and a longer median survival duration of 4.8mos., the same RPSFTM analyses were performed with consistent results
Ref: Amylyx | Image: Amylyx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
